Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 8Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Sarcoma 4Endometrial Neoplasms 4Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Solid Tumors 1Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Doxorubicin 14Radiotherapy 10Ifosfamide 10Trabectedin 7pazopanib 4Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3Chemotherapy, Adjuvant 3temsirolimus 2romidepsin 2ribociclib 2pegfilgrastim 2eribulin 2cixutumumab 2brigimadlin 2belinostat 2Vincristine 2Sunitinib 2Radiotherapy, Conformal 2Gemcitabine 2Epirubicin 2Dexamethasone 2Dactinomycin 2Carboplatin 2soblidotin 1sitravatinib 1siremadlin 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liposarcoma × ridaforolimus × Clear all
NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
216 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡